Provision of diamorphine (heroin) by prescription for drug dependency: Issues and recommendations

CNS Drugs

Volumn 11, Issue 4, 1999, Pages 253-262

  Bammer, Gabriele ^a  

^a The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; METHADONE;

CLINICAL TRIAL; DRUG DEPENDENCE TREATMENT; DRUG WITHDRAWAL; HEROIN DEPENDENCE; HUMAN; MEDICAL ETHICS; METHADONE TREATMENT; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0032893244     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199911040-00002     Document Type: Review

References (39)

1. 1. Strang J, Gossop M, editors. Heroin addiction and drug policy: the British system. Oxford: Oxford University Press, 1994
2. 2. Strang J. 'The British system': past, present and future. Int Rev Psychiatry 1989; 1: 109-20
3. 3. Stimson G. British drug policies in the 1980s: a preliminary analysis and suggestions for research. Br J Addict 1987; 82: 477-88
4. 4. Koran LM. Heroin maintenance for heroin addicts: issues and evidence. N Engl J Med 1973: 654-60
5. 5. Lewis E Jr. A heroin maintenance program in the United States? JAMA 1973; 223: 539-46
6. 6. Trebach A. The heroin solution. New Haven, CT: Yale University Press, 1982
7. 7. Bayer R. Heroin maintenance, the Vera proposal and narcotics reform: an analysis of the debate 1971-1973. Contemp Drug Problems 1975; 4: 297-321
8. 8. Robinson CD. A proposal for a heroin maintenance experiment in New York City: the limits of reform strategy. Contemp Crises 1978; 2: 1-26
9. 9. Strang J, Sheridan J. Heroin prescribing in the 'British System' of the mid 1990s: data from the 1995 national survey of community pharmacies in England and Wales. Drug Alcohol Rev 1997; 16: 7-16
10. 10. Ward J, Mattick RP, Hall W, editors. Methadone maintenance treatment and other opioid replacement therapies. Amsterdam: Harwood Academic, 1998
11. 11. Gerstein DR, Johnson RA, Harwood HJ, et al. Evaluating recovery services: the California Drug and Alcohol Treatment Assessment (CALDATA). General report submitted to the State of California Department of Alcohol and Drug Programs by National Opinion Research Centre at the University of Chicago and Lewin-VHI Inc., Fairfax, VA. Sacramento, CA: California Department of Alcohol and Drug Programs, 1994
12. 12. National Institute on Drug Abuse. Drug abuse treatment: an economical approach to addressing the drug problem in America. Rockville, MD: US Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, 1991
13. 13. Rydell CP, Everingham SS. Controlling cocaine: supply versus demand reduction. Santa Monica, CA: RAND Drug Policy Research Center, 1994
14. 14. Uchtenhagen A, Gutzwiller F, Dobler-Mikola A, et al. Programme for a medical prescription of narcotics: a synthesis of results. Eur Addict Res 1997; 3: 160-3
15. 15. Central Committee on the Treatment of Heroin Addicts. Investigating the medical prescription of heroin: a randomized trial to evaluate the effectiveness of medically co-prescribed heroin and oral methadone, compared to oral methadone alone in chronic, treatment-refractory heroin addicts. Utrecht: Central Committee on the Treatment of Heroin Addicts, 1997
16. 16. Bammer G. Report and recommendations of stage 2 feasibility research into the controlled availability of opioids. Canberra: National Centre for Epidemiology and Population Health, the Australian National University and the Australian Institute of Criminology, 1995. Report and working papers available from: http://www-nceph.anu.edu.au/pub/opioids/opioids.htm [accessed 1999 Feb 17]
17. 17. Bammer G, Douglas RM. The ACT heroin trial proposal: an overview. Med J Aust 1996; 164: 690-2
18. 18. Moore DL, Bernard S. Clinical trials in women's health research. Part I: the drug discovery and development process. J Womens Health 1996; 5: 103-7
19. 19. Moore DL, Bernard S. Clinical trials in women's health research. Part II: phase IV clinical research and beyond. J Womens Health 1996; 5: 303-9
20. 20. Bammer G. The ACT heroin trial: intellectual, practical and political challenges. The 1996 Leonard Ball Oration. Drug Alcohol Rev 1997; 16: 287-96
21. 21. Bammer G, Dobler-Mikola A, Fleming PM, et al. Prescribing heroin to dependent users - integrating science and politics. Science 1999. In press
22. 22. Bammer G. Should the controlled provision of heroin be a treatment option? Australian feasibility considerations. Addiction 1993; 88: 467-75
23. 23. Hartnoll RL, Mitcheson MC, Battersby A, et al. Evaluation of heroin maintenance in controlled trial. Arch Gen Psychiatry 1980; 37: 877-84
24. 24. Perneger TV, Giner F, del Rio M, et al. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998; 317: 13-8
25. 25. Uchtenhagen A, Gutzwiller F, Dobler-Mikola A. Versuche fuer eine aerztliche Verschreibung von Betaeubungsmitteln. Abschlussbericht der Forschungsbeauftragten. Zurich: Institut fuer Suchtforchung in Verbindung mir der Universitaet Zuerich und Institut fuer Sozial-und Praeventivmedizin der Universitaet Zuerich, 1997. A monograph in English based on this report will be published in 1999: Uchtenhagen A, Gutzwiller F, Dobler-Mikola A, editors. Medical Prescription of Narcotics Research Programme. Final report of the principal investigators. Basel: Karger
26. 26. Uchtenhagen A, Dobler-Mikola A, Gutzwiller F. Medically controlled prescription of narcotics: a Swiss national project. Int J Drug Policy 1996; 7: 31-6
27. 27. Killias M, Uchtenhagen A. Does medical heroin prescription reduce delinquency among drug-addicts? On the evaluation of the Swiss heroin prescription projects and its methodology. Studies Crime Crime Prevention 1996; 5: 245-56
28. 28. McCusker C, Davies M. Prescribing drug of choice to illicit heroin users: the experience of a U.K. community drug team. J Subst Abuse Treat 1996; 13: 521-31
29. 29. Metrebian N, Shanahan W, Wells B, et al. Feasibility of prescribing injectable heroin and methadone to opiate-dependent users: associated health gains and harm reductions. Med J Aust 1998; 168: 596-600
30. 30. Stimson GV. Heroin and behaviour: diversity among addicts attending London clinics. Shannon: Irish University Press, 1973
31. 31. Stimson GV, Oppenheimer E. Heroin addiction: treatment and control in Britain. London: Tavistock, 1982
32. 32. Bammer G. Multidisciplinary policy research - an Australian experience. Prometheus 1997; 15: 27-39
33. 33. Ostini R, Bammer G, Dance P, et al. The ethics of experimental heroin maintenance. J Med Ethics 1993; 19: 175-82
34. 34 Rihs-Middel M. The Swiss Federal Office of Public Health's research strategy and the prescription of narcotics. In: Lewis D, Gear C, Laeubli Loud M, et al., editors. The medical prescription of narcotics: scientific foundations and practical experiences. Seattle: Hogrefe and Huber, 1997: 4-11
35. 35. Norberry J. Ethical issues. In: Feasibility research into the controlled availability of opioids. Vol 2. Canberra: National Centre for Epidemiology and Population Health, Australian National University, 1991: 177-86
36. 36. Bammer G, Tunnicliff D, Chadwick-Masters J. How could an influx of users be prevented if Canberra introduces a trial of controlled availability of heroin? Feasibility research into the controlled availability of opioids. Stage 2, working papers number 9. Canberra: National Centre for Epidemiology and Population Health, Australian National University and the Australian Institute of Criminology, 1994
37. 37. Dance P, Crawford D, Ostini R, et al. Is it time for a heroin maintenance program? Views of users and ex-users. Addict Res 1997; 5: 383-93
38. 38. Chesher GB. Understanding the opioid analgesics and their effects on skills performance. Alcohol Drugs Driving 1989; 5: 111-38
39. 39. Finnegan LP, Kandall SR. Maternal and neonatal effects of alcohol and drugs. In: Lowinson JH, Ruiz P, Millman RB, editors. Substance abuse: a comprehensive textbook. 2nd ed. Baltimore: Williams and Wilkins, 1992: 628-56